Analysts have slightly reduced their fair value estimate for Fresenius Medical Care to approximately $49.74 from $50.26. This change reflects marginal adjustments in growth projections and risk assumptions.
What's in the News
- Fresenius Medical Care AG issued earnings guidance for fiscal 2025, forecasting positive to low-single-digit percent revenue growth compared to the previous year. Operating income excluding special items is expected to increase by a high-teens to high-twenties percent rate compared to the prior year (Key Developments).
- The company reported a buyback tranche update, announcing that from June 17, 2025 to June 30, 2025, no shares were repurchased. This completed the repurchase of 0 shares under the buyback plan initially announced on June 17, 2025 (Key Developments).
Valuation Changes
- The Fair Value Estimate has decreased slightly from $50.26 to $49.74.
- The Discount Rate has risen marginally to 5.02% from 4.99%.
- The Revenue Growth projection has decreased slightly from 3.57% to 3.53%.
- The Net Profit Margin is expected to improve modestly, increasing from 6.20% to 6.22%.
- The Future P/E Ratio estimate has declined moderately from 12.69x to 12.53x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.